A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Trial Profile

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs LJPC 501 (Primary)
  • Indications Hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHOS-3
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 06 Mar 2018 Results presented in a La Jolla Pharmaceutical company's media release.
    • 06 Mar 2018 According to a La Jolla Pharmaceutical Company media release, results from the study will be presented at the 23rd International Conference on Advances in Critical Care Nephrology - AKI & CRRT 2018.
    • 25 Feb 2018 According to a La Jolla Pharmaceutical Company media release, the abstract was published in the January Supplement of Critical Care Medicine and online.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top